SNPMiner Trials (Home Page)
Report for SNP rs9557195
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will test the influence of rs9557195 genoty (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes, mRNA expression of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migraton assay.
NCT03633409 Inflammatory Bowel Diseases MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine
Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism.
Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism EBI2 is a risk gene for inflammatory bowel diseases (rs9557195).
The investigators will test the influence of rs9557195 genoty (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes, mRNA expression of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migraton assay.
EBI2 expression - dependent on rs9557195 allele status (FACS).
EBI2 levels in PBMCs will be determined by FACS, and compared according to allele status of rs9557195.
EBI2 expression - dependent on rs9557195 allele status (RT-PCR).
EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195.
UBAC2 expression - dependent on rs9557195 allele status (RT-PCR).
UBAC2 levels in PBMCs will be determined by RT-PCR, and compared according to 2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195.
Motility of PBMCs dependent on rs9557195 allele status (Boyden chamber).
motility of PBMCs will be assessed using the Boyden chamber and compared according to allele status of rs9557195.
medically controlled arterial hypertension, occupational asthma) may be present Exclusion Criteria: none Inflammatory Bowel Diseases Inflammatory Bowel Diseases EBI2 is a risk gene for inflammatory bowel diseases (rs9557195).
The investigators will test the influence of rs9557195 genotype (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes (by FACS using an EBI2-antibody), mRNA expression (by qPCR) of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migration assay.
Primary Outcomes
Description: EBI2 levels in PBMCs will be determined by FACS, and compared according to allele status of rs9557195
Measure: EBI2 expression - dependent on rs9557195 allele status (FACS) Time: at time of inclusion into the studySecondary Outcomes
Description: EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195
Measure: EBI2 expression - dependent on rs9557195 allele status (RT-PCR) Time: at time of inclusion into the studyDescription: UBAC2 levels in PBMCs will be determined by RT-PCR, and compared according to 2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195
Measure: UBAC2 expression - dependent on rs9557195 allele status (RT-PCR) Time: at time of inclusion into the studyDescription: motility of PBMCs will be assessed using the Boyden chamber and compared according to allele status of rs9557195
Measure: Motility of PBMCs dependent on rs9557195 allele status (Boyden chamber) Time: at time of inclusion into the studyDescription: We will compare EBI2 expression as determined by FACS in individuals with infliximab and vedolizumab treatment
Measure: EBI2-expression (FACS) in individuals treated with infliximab vs. vedolizumab Time: at time of inclusion into the studyDescription: We will compare EBI2 expression (determined by FACS) in IBD patients with severe disease, in remission and in healthy volunteers
Measure: EBI2-expression (FACS) according to gut inflammation Time: at time of inclusion into the study